Chromosome abnormalities in ovarian adenocarcinoma: II. Prognostic impact of nonrandom chromosome abnormalities in 244 cases

Genes Chromosomes and Cancer

Volumn 25, Issue 1, 1999, Pages 46-52

  Taetle, Raymond ^a,c   Aickin, Mikel ^a   Panda, Lita ^a   Emerson, Julia ^a   Denise, Roe ^a   Thompson, Floyd ^a   Davis, John ^a   Trent, Jeffrey ^b   Alberts, David ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; PLATINUM;

ARTICLE; CANCER GRADING; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME BREAKAGE; CHROMOSOME REARRANGEMENT; FEMALE; GENOME; HUMAN; MAJOR CLINICAL STUDY; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA; CHROMOSOME ABERRATIONS; CHROMOSOME BREAKAGE; CHROMOSOME DISORDERS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

FALLOPIA;

EID: 0032913524     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(199905)25:1<46::AID-GCC7>3.0.CO;2-O     Document Type: Article

References (36)

1. Alberts DS, Taetle R, Frutiger Y, Heddens D, Laptalo L, Einspahr J, Gilmore D, Grogan T. 1998. Multidrug resistance (MDR-1) expression as an independent risk factor for poor survival in optimal stage III ovarian cancer (OVCA). Pr ASCO 17:351A (Abstract).
2. Bello MJ, Rey JA. 1990. Chromosome aberrations in metastatic ovarian cancer: relationship with abnormalities in primary tumors. Int J Cancer 45:50-54.
3. Brooks DJ, Woodward S, Thompson FH, Dos Santos B, Russell M, Yang J-M, Guan X-Y, Trent J, Alberts DS, Taetle R. 1996. Expression of the Zn-finger gene EVI-1 in ovarian and other cancers. Br J Cancer 74:1518-1525.
4. Caron H, van Sluis P, de Kraker J, Bökkerink J, Egeler M, Laureys G, Slater R, Westerveld A, Voûte PA, Versteeg R. 1996. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 334:225-230.
5. Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML. 1997. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res 3:999-1007.
6. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, Chen Y, Su YA, Trent JM. 1996. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 14:457-460.
7. Eipers PG, Barnoski BL, Han J, Carroll AJ, Kidd VJ. 1991. Localization of the expressed human p58 protein kinase chromosomal gene to chromosome 1p36 and a highly related sequence to chromosome 15. Genomics 11:621-629.
8. International Federation of Gynecology and Obstetrics. 1971. Classification and staging of malignant tumors in the female pelvis. Acta Obstet Gynaecol Scand 50:1-7.
9. Kong KM, Biesterveld A, Virmani A, Wistuba I, Sekido Y, Bader SA, Ahmadian M, Ong ST, Rassool FV, Zimmerman PV, Giaccone G, Gazdar AF, Minna JD. 1997. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res 57:2256-2267.
10. Gallion HH, Powell DE, Smith LW, Morrow JK, Martin AW, van Nagell JR, Donaldson ES. 1990. Chromosome abnormalities in human epithelial ovarian malignancies. Gynecol Oncol 38:473-477.
11. Gemma A, Hagiwara K, Ke Y, Burke LM, Khan MA, Nagashima M, Bennett WP, Harris CC. 1997. FHIT mutations in human primary gastric cancer. Cancer Res 57:1435-1437.
12. ISCN. 1995. International System for Human Cytogenetic Nomenclature. Basel: S. Karger.
13. Jenkins RB, Bartlet D Jr, Stalboerger P, Persons D, Dahl RJ, Podratz K, Keeney G, Hartmann L. 1993. Cytogenetic studies of epithelial ovarian carcinoma. Cancer Genet Cytogenet 71:76-86.
14. Johansson B, Mertens F, Mitelman F. 1996. Primary vs secondary neoplasia-associated chromosomal abnormalities-balanced rearrangements vs. genomic imbalances? Genes Chromosomes Cancer 16:155-163.
15. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan J-C , Valent A, Minty A, Chalon P, Lelias J-M, Dumont X, Ferrara P, McKeon F, Caput D. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809-819.
16. Kalbfleisch JD, Prentice RL, Russ L. 1980. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons.
17. Mertens F, Johansson B. Mitelman F. 1994. Isochromosomes in neoplasia. Genes Chromosomes Cancer 10:221-230.
18. Miele ME, Robertson G, Lee J-H. Coleman A, McGary CT, Fisher PB, Lugo TG, Welch DR. 1996. Metastasis suppressed, but tumorigenicity and local invasiveness unaffected, in the human melanoma cell line MelJuSo after introduction of human chromosomes 1 or 6. Mol Carcinogen 15:284-299.
19. Mitelman F, Mertens F, Johansson B. 1997. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet 15:417-474.
20. Nichols J, Nimer SD. 1992. Transcription factors, translocations, and leukemia. Blood 80:2953-2963.
21. Pedersen-Bjergaard J, Rowley JD. 1994. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 83:2780-2786.
22. Pejovic T, Heim S, Mandahl N, Bladetorp B. Elmfors B, Floderus U-M, Furgyik S, Helm G, Himmelman A, Willen H, Mitelman F. 1992a. Chromosome aberrations in 35 primary ovarian carcinomas. Genes Chromosomes Cancer 4:58-68.
23. Pejovic T, Himmelman A, Heim S, Mandahl N, Floderus U-M. Furgyik S, Elmfors B, Helm G, Willen H, Mitelman F. 1992b. Prognostic impact of chromosome aberrations in ovarian cancer. Br J Cancer 65:282-286.
24. Peto R, Pike M, Armitage P, Breslow N, Cox DR, Howard WV, Mantel N, McPherson K, Peto J, Smith P. 1976. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 34:585-612.
25. Peto R, Pike M, Armitage P, Breslow NK, Cox DR, Howard S, Mantel N, McPherson K, Peto J, Smith P. 1977. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1-39.
26. Roberts CG, Tettersall M. 1990. Cytogenetic study of solid ovarian tumors. Cancer Genet Cytogenet 48:243-253.
27. Russel P, Karnsworth A. 1997. Surgical pathology of ovaries. New York: Churchill Livingstone.
28. Sheer D, Squire J. 1996. Clinical applications of genetic rearrangements in cancer. Semin Cancer Biol 7:25-32.
29. Sorensen P, Triche T. 1996. Gene fusions encoding chimaeric transcription factors in solid tumours. Semin Cancer Biol 7:3-14.
30. Taetle R, Aickin M, Yang J-M, Panda L, Emerson J, Roe D, Adair L, Thompson F, Liu Y, Wisner L, Davis JR, Trent J, Alberts DS. 1998. Chromosome abnormalities in ovarian adenocarcinoma. I. Non-random chromosome abnormalities from 244 cases. Genes Chromosomes Cancer (in press).
31. Tanaka K, Yanoshita R, Konishi M, Oshimura M, Maeda Y, Mori T, Miyaki M. 1993. Suppression of tumourgenicity in human colon carcinoma cells by introduction of normal chromosome 1p36 region. Oncogene 8:2253-2258.
32. Testa JR. 1997. Chromosome translocations in human cancer. Cell Growth Different 1:97-101.
33. Thompson FH, Emerson J, Alberts D, Liu Y, Guan X-Y, Burgess A, Fox S, Taetle R, Weinstein R, Makar R, Powell D, Trent J. 1994. Clonal chromosome abnormalities in 54 cases of ovarian carcinoma. Cancer Genet Cytogenet 73:33-45.
34. Versteeg R, Caron H, Cheng NC, van der Drift P, Slater R, Westerveld A, Voûte PA, Delattre O, Laureys G, van Roy N, Speleman F. 1995. 1p36: every subband a suppressor? Eur J Cancer 31A:538-541.
35. Whang-Peng J, Knutsen T, Douglass EC, Chu E, Ozols RF, Hogan WM, Young RC. 1984. Cytogenetic studies in ovarian cancer. Cancer Genet Cytogenet 11:91-106.
36. Zhang L, Zhou W. Velculescu V, Kern S, Hruban R. Hamilton S, Vogelstein B, Kinzler K. 1997. Gene expression profiles in normal and cancer cells. Science 276:1268-1272.